A
An Coosemans
Researcher at Katholieke Universiteit Leuven
Publications - 87
Citations - 2164
An Coosemans is an academic researcher from Katholieke Universiteit Leuven. The author has contributed to research in topics: Ovarian cancer & Immunotherapy. The author has an hindex of 20, co-authored 70 publications receiving 1500 citations. Previous affiliations of An Coosemans include Catholic University of Leuven.
Papers
More filters
Journal ArticleDOI
Clinical management of uterine sarcomas
TL;DR: This Review discusses pathology, preoperative diagnosis, and standard treatment of uterine leiomyosarcoma and low-grade ESS (distinct from undifferentiated uterine sarcomas), with an emphasis on targeted treatment.
Journal ArticleDOI
Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death
Abhishek D. Garg,Lorenzo Galluzzi,Lionel Apetoh,Lionel Apetoh,Thaïs Baert,Raymond B. Birge,José Manuel Bravo-San Pedro,Karine Breckpot,David Brough,Ricardo A. Chaurio,Mara Cirone,An Coosemans,Pierre Coulie,Dirk De Ruysscher,Luciana Dini,Peter de Witte,Aleksandra M. Dudek-Peric,Alberto Faggioni,Jitka Fucikova,Udo S. Gaipl,Jakub Golab,Marie-Lise Gougeon,Michael R. Hamblin,Akseli Hemminki,Martin Herrmann,James W. Hodge,Oliver Kepp,Guido Kroemer,Dmitri V. Krysko,Walter Land,Frank Madeo,Angelo A. Manfredi,Stephen R. Mattarollo,Christian Maueröder,Nicolò Merendino,Gabriele Multhoff,Thomas Pabst,Jean-Ehrland Ricci,Chiara Riganti,Erminia Romano,Nicole Rufo,Mark J. Smyth,Mark J. Smyth,Jürgen Sonnemann,Radek Spisek,John Stagg,Erika Vacchelli,Peter Vandenabeele,Lien Vandenberk,Benoît Van den Eynde,Stefaan Van Gool,Francesca Velotti,Laurence Zitvogel,Patrizia Agostinis +53 more
TL;DR: The main molecular, immunological, preclinical, and clinical aspects of ICD are summarized and tabulate in an attempt to capture the essence of this phenomenon, and identify future challenges for this rapidly expanding field of investigation.
Journal ArticleDOI
Trial Watch: Dendritic Cell Vaccination for Cancer Immunotherapy
Jenny Sprooten,Jolien Ceusters,An Coosemans,Patrizia Agostinis,Steven De Vleeschouwer,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi,Abhishek D. Garg +8 more
TL;DR: Clinical interest is being refocused on DC-based vaccines as combinatorial partners for T cell-targeting immunotherapies, reflecting the widespread immunosuppression within tumors.
Journal ArticleDOI
Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study
Wouter Froyman,Chiara Landolfo,Chiara Landolfo,Bavo De Cock,Laure Wynants,Povilas Sladkevicius,Antonia Carla Testa,Caroline Van Holsbeke,Ekaterini Domali,Robert Fruscio,Elisabeth Epstein,Maria José dos Santos Bernardo,Dorella Franchi,Marek Kudla,Valentina Chiappa,Juan Luis Alcázar,F. Leone,F. Buonomo,L. Hochberg,Maria Elisabetta Coccia,Stefano Guerriero,Nandita Deo,Ligita Jokubkiene,J. Kaijser,An Coosemans,Ignace Vergote,Jan Y Verbakel,Jan Y Verbakel,Tom Bourne,Tom Bourne,Ben Van Calster,Ben Van Calster,Lil Valentin,Dirk Timmerman +33 more
TL;DR: The results suggest that the risk of malignancy and acute complications is low if adnexal masses with benign ultrasound morphology are managed conservatively, which could be of value when counselling patients, and supports conservative management of adnexAl masses classified as benign by use of ultrasound.
Journal ArticleDOI
Screening for uterine tumours
TL;DR: The most prevalent uterine tumours are leiomyomas, which are benign and have a prevalence of about 50% at menopause, and reliable serum markers for sarcomas are lacking, and mass screening for uterine malignancies is not feasible or effective.